RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jose L. Lopez-Ribot to Humans

Back to Details
This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Humans.
Jose L. Lopez-Ribot
Connection Strength
0.843
Humans
  1. Ramage G, Borghi E, Rodrigues CF, Kean R, Williams C, Lopez-Ribot J. Our current clinical understanding of Candida biofilms: where are we two decades on? APMIS. 2023 Nov; 131(11):636-653.
    View in: PubMed
    Score: 0.044
  2. Ajetunmobi OH, Wall G, Bonifacio BV, Montelongo-Jauregui D, Lopez-Ribot JL. A 384-Well Microtiter Plate Model for Candida Biofilm Formation and Its Application to High-Throughput Screening. Methods Mol Biol. 2023; 2658:53-64.
    View in: PubMed
    Score: 0.044
  3. Wall G, Chen E, Hull MV, Lopez-Ribot JL. Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation. Front Cell Infect Microbiol. 2020; 10:597931.
    View in: PubMed
    Score: 0.038
  4. Wall G, Lopez-Ribot JL. Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity. Antimicrob Agents Chemother. 2020 08 20; 64(9).
    View in: PubMed
    Score: 0.037
  5. Montelongo-Jauregui D, Saville SP, Lopez-Ribot JL. Contributions of Candida albicans Dimorphism, Adhesive Interactions, and Extracellular Matrix to the Formation of Dual-Species Biofilms with Streptococcus gordonii. mBio. 2019 06 18; 10(3).
    View in: PubMed
    Score: 0.034
  6. Romo JA, Pierce CG, Esqueda M, Hung CY, Saville SP, Lopez-Ribot JL. In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation. Front Cell Infect Microbiol. 2018; 8:227.
    View in: PubMed
    Score: 0.032
  7. Vila T, Lopez-Ribot JL. Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors. Antimicrob Agents Chemother. 2017 01; 61(1).
    View in: PubMed
    Score: 0.029
  8. Vila T, Romo JA, Pierce CG, McHardy SF, Saville SP, Lopez-Ribot JL. Targeting Candida albicans filamentation for antifungal drug development. Virulence. 2017 02 17; 8(2):150-158.
    View in: PubMed
    Score: 0.028
  9. Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. Virulence. 2017 02 17; 8(2):138-142.
    View in: PubMed
    Score: 0.028
  10. Uppuluri P, Lopez-Ribot JL. Go Forth and Colonize: Dispersal from Clinically Important Microbial Biofilms. PLoS Pathog. 2016 Feb; 12(2):e1005397.
    View in: PubMed
    Score: 0.027
  11. Pierce CG, Srinivasan A, Ramasubramanian AK, L?pez-Ribot JL. From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr. 2015 Jun; 3(3).
    View in: PubMed
    Score: 0.026
  12. Pierce CG, Saville SP, Lopez-Ribot JL. High-content phenotypic screenings to identify inhibitors of Candida albicans biofilm formation and filamentation. Pathog Dis. 2014 Apr; 70(3):423-31.
    View in: PubMed
    Score: 0.024
  13. Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, L?pez-Ribot JL. Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol. 2013 Oct; 13(5):726-30.
    View in: PubMed
    Score: 0.023
  14. Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov. 2013 Sep; 8(9):1117-26.
    View in: PubMed
    Score: 0.022
  15. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, K?hler JR, Kadosh D, Lopez-Ribot JL. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 2010 Mar 26; 6(3):e1000828.
    View in: PubMed
    Score: 0.018
  16. Uppuluri P, Pierce CG, L?pez-Ribot JL. Candida albicans biofilm formation and its clinical consequences. Future Microbiol. 2009 Dec; 4(10):1235-7.
    View in: PubMed
    Score: 0.018
  17. Uppuluri P, Dinakaran H, Thomas DP, Chaturvedi AK, Lopez-Ribot JL. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J Clin Microbiol. 2009 Dec; 47(12):4078-83.
    View in: PubMed
    Score: 0.017
  18. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. Crit Rev Microbiol. 2009; 35(4):340-55.
    View in: PubMed
    Score: 0.016
  19. Pierce CG, Thomas DP, L?pez-Ribot JL. Effect of tunicamycin on Candida albicans biofilm formation and maintenance. J Antimicrob Chemother. 2009 Mar; 63(3):473-9.
    View in: PubMed
    Score: 0.016
  20. Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J. Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence. Mycopathologia. 2009 Feb; 167(2):55-63.
    View in: PubMed
    Score: 0.016
  21. Ramage G, Wickes BL, L?pez-Ribot JL. Inhibition on Candida albicans biofilm formation using divalent cation chelators (EDTA). Mycopathologia. 2007 Dec; 164(6):301-6.
    View in: PubMed
    Score: 0.015
  22. Thomas DP, Pitarch A, Monteoliva L, Gil C, Lopez-Ribot JL. Proteomics to study Candida albicans biology and pathogenicity. Infect Disord Drug Targets. 2006 Dec; 6(4):335-41.
    View in: PubMed
    Score: 0.014
  23. Thomas DP, Bachmann SP, Lopez-Ribot JL. Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics. 2006 Nov; 6(21):5795-804.
    View in: PubMed
    Score: 0.014
  24. Ramage G, Mart?nez JP, L?pez-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 2006 Nov; 6(7):979-86.
    View in: PubMed
    Score: 0.014
  25. Saville SP, Thomas DP, L?pez-Ribot JL. Use of genome information for the study of the pathogenesis of fungal infections and the development of diagnostic tools. Rev Iberoam Micol. 2005 Dec; 22(4):238-41.
    View in: PubMed
    Score: 0.013
  26. L?pez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol. 2005 Jun 21; 15(12):R453-5.
    View in: PubMed
    Score: 0.013
  27. L?pez-Ribot JL, Casanova M, Murgui A, Mart?nez JP. Antibody response to Candida albicans cell wall antigens. FEMS Immunol Med Microbiol. 2004 Jul 01; 41(3):187-96.
    View in: PubMed
    Score: 0.012
  28. Monteagudo C, Viudes A, Lazzell A, Martinez JP, Lopez-Ribot JL. Tissue invasiveness and non-acidic pH in human candidiasis correlate with "in vivo" expression by Candida albicans of the carbohydrate epitope recognised by new monoclonal antibody 1H4. J Clin Pathol. 2004 Jun; 57(6):598-603.
    View in: PubMed
    Score: 0.012
  29. Li X, Brown N, Chau AS, L?pez-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004 Jan; 53(1):74-80.
    View in: PubMed
    Score: 0.012
  30. Redding SW, Kirkpatrick WR, Saville S, Coco BJ, White W, Fothergill A, Rinaldi M, Eng T, Patterson TF, Lopez-Ribot J. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol. 2003 Feb; 41(2):619-22.
    View in: PubMed
    Score: 0.011
  31. Bachmann SP, Patterson TF, L?pez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002 Jun; 40(6):2228-30.
    View in: PubMed
    Score: 0.010
  32. Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother. 2001 Sep; 45(9):2475-9.
    View in: PubMed
    Score: 0.010
  33. Ramage G, Vande Walle K, Wickes BL, L?pez-Ribot JL. Biofilm formation by Candida dubliniensis. J Clin Microbiol. 2001 Sep; 39(9):3234-40.
    View in: PubMed
    Score: 0.010
  34. Cheng T, Torres NS, Chen P, Srinivasan A, Cardona S, Lee GC, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. A Facile High-Throughput Model of Surface-Independent Staphylococcus aureus Biofilms by Spontaneous Aggregation. mSphere. 2021 04 28; 6(2).
    View in: PubMed
    Score: 0.010
  35. Lopez-Ribot JL, McAtee RK, Kirkpatrick WR, La Valle R, Patterson TF. Low levels of antigenic variability in fluconazole-susceptible and -resistant Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Clin Diagn Lab Immunol. 1999 Sep; 6(5):665-70.
    View in: PubMed
    Score: 0.009
  36. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1999 Jul; 43(7):1621-30.
    View in: PubMed
    Score: 0.009
  37. Wall G, Montelongo-Jauregui D, Vidal Bonifacio B, Lopez-Ribot JL, Uppuluri P. Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Curr Opin Microbiol. 2019 12; 52:1-6.
    View in: PubMed
    Score: 0.008
  38. Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson TF. Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 1998 Nov; 42(11):2932-7.
    View in: PubMed
    Score: 0.008
  39. Liu NN, Uppuluri P, Broggi A, Besold A, Ryman K, Kambara H, Solis N, Lorenz V, Qi W, Acosta-Zald?var M, Emami SN, Bao B, An D, Bonilla FA, Sola-Visner M, Filler SG, Luo HR, Engstr?m Y, Ljungdahl PO, Culotta VC, Zanoni I, Lopez-Ribot JL, K?hler JR. Intersection of phosphate transport, oxidative stress and TOR signalling in Candida albicans virulence. PLoS Pathog. 2018 07; 14(7):e1007076.
    View in: PubMed
    Score: 0.008
  40. Lara HH, Guisbiers G, Mendoza J, Mimun LC, Vincent BA, Lopez-Ribot JL, Nash KL. Synergistic antifungal effect of chitosan-stabilized selenium nanoparticles synthesized by pulsed laser ablation in liquids against Candida albicans biofilms. Int J Nanomedicine. 2018; 13:2697-2708.
    View in: PubMed
    Score: 0.008
  41. Actis L, Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK, Ong JL. Effect of silver nanoparticle geometry on methicillin susceptible and resistant Staphylococcus aureus, and osteoblast viability. J Mater Sci Mater Med. 2015 Jul; 26(7):215.
    View in: PubMed
    Score: 0.006
  42. Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. Drug Discov Today Technol. 2014 Mar; 11:65-71.
    View in: PubMed
    Score: 0.006
  43. Srinivasan A, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. High-throughput nano-biofilm microarray for antifungal drug discovery. mBio. 2013 Jun 25; 4(4).
    View in: PubMed
    Score: 0.006
  44. Banerjee M, Uppuluri P, Zhao XR, Carlisle PL, Vipulanandan G, Villar CC, L?pez-Ribot JL, Kadosh D. Expression of UME6, a key regulator of Candida albicans hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. Eukaryot Cell. 2013 Feb; 12(2):224-32.
    View in: PubMed
    Score: 0.005
  45. Chambers JP, Yu JJ, Jupelli M, Weintraub ST, Lopez-Ribot JL, Valdes JJ, Arulanandam BP. Alpha-1 antitrypsin is markedly decreased following pulmonary F. tularensis challenge. Front Cell Infect Microbiol. 2011; 1:20.
    View in: PubMed
    Score: 0.005
  46. Dahlan AA, Haveman CW, Ramage G, Lopez-Ribot JL, Redding SW. Sodium hypochlorite, chlorhexidine gluconate, and commercial denture cleansers as disinfecting agents against Candida albicans: An in vitro comparison study. Gen Dent. 2011 Nov-Dec; 59(6):e224-9.
    View in: PubMed
    Score: 0.005
  47. Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Adhesion of Candida albicans to endothelial cells under physiological conditions of flow. Infect Immun. 2009 Sep; 77(9):3872-8.
    View in: PubMed
    Score: 0.004
  48. Grubb SE, Murdoch C, Sudbery PE, Saville SP, Lopez-Ribot JL, Thornhill MH. Candida albicans-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. Infect Immun. 2008 Oct; 76(10):4370-7.
    View in: PubMed
    Score: 0.004
  49. Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C, L?pez-Ribot JL, Kadosh D. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell. 2008 Apr; 19(4):1354-65.
    View in: PubMed
    Score: 0.004
  50. S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. J Clin Microbiol. 2005 Aug; 43(8):4159-62.
    View in: PubMed
    Score: 0.003
  51. S?nchez-Vargas LO, Ortiz-L?pez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gait?n-Cepeda LA, Quind?s G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 2005 Jun; 22(2):83-92.
    View in: PubMed
    Score: 0.003
  52. Ramage G, Tomsett K, Wickes BL, L?pez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul; 98(1):53-9.
    View in: PubMed
    Score: 0.003
  53. Hernandez S, L?pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004 Apr; 48(4):1382-3.
    View in: PubMed
    Score: 0.003
  54. Viudes A, Pem?n J, Cant?n E, Ubeda P, L?pez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002 Nov; 21(11):767-74.
    View in: PubMed
    Score: 0.003
  55. Martinez M, L?pez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol. 2002 Sep; 40(9):3135-9.
    View in: PubMed
    Score: 0.003
  56. Perea S, L?pez-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002 Jun; 46(6):1695-703.
    View in: PubMed
    Score: 0.003
  57. Viudes A, Pem?n J, Cant?n E, Salavert M, Ubeda P, L?pez-Ribot JL, Gobernado M. Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis. 2002 Apr; 21(4):294-9.
    View in: PubMed
    Score: 0.003
  58. Mart?nez M, L?pez-Ribot JL, Kirkpatrick WR, Bachmann SP, Perea S, Ruesga MT, Patterson TF. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother. 2002 Mar; 49(3):515-24.
    View in: PubMed
    Score: 0.003
  59. Viudes A, Cant?n E, Pem?n J, L?pez-Ribot JL, Gobernado M. [Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis]. Rev Esp Quimioter. 2002 Mar; 15(1):32-42.
    View in: PubMed
    Score: 0.003
  60. Perea S, L?pez-Ribot JL, Kirkpatrick WR, McAtee RK, Santill?n RA, Mart?nez M, Calabrese D, Sanglard D, Patterson TF. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001 Oct; 45(10):2676-84.
    View in: PubMed
    Score: 0.002
  61. Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill AW, Rinaldi MG, Patterson TF. Candida dubliniensis in radiation-induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun; 91(6):659-62.
    View in: PubMed
    Score: 0.002
  62. Kirkpatrick WR, Lopez-Ribot JL, McAtee RK, Patterson TF. Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions. J Clin Microbiol. 2000 Feb; 38(2):902-4.
    View in: PubMed
    Score: 0.002
  63. Monteagudo C, Lopez-Ribot JL, Murgui A, Casanova M, Chaffin WL, Martinez JP. Immunodetection of CD45 epitopes on the surface of Candida albicans cells in culture and infected human tissues. Am J Clin Pathol. 2000 Jan; 113(1):59-63.
    View in: PubMed
    Score: 0.002
  64. Kirkpatrick WR, Revankar SG, Mcatee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol. 1998 Oct; 36(10):3007-12.
    View in: PubMed
    Score: 0.002
  65. Casanova M, Lopez-Ribot JL, Monteagudo C, Llombart-Bosch A, Sentandreu R, Martinez JP. Identification of a 58-kilodalton cell surface fibrinogen-binding mannoprotein from Candida albicans. Infect Immun. 1992 Oct; 60(10):4221-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support